Results 11 to 20 of about 198,463 (306)
Regulation of Mutant p53 protein expression [PDF]
Frontiers in Oncology, 2015 For several decades p53 has been detected in cancer biopsies by virtue of its high protein expression level and considered indicative of mutation. Surprisingly, however, mouse genetic studies revealed that mutant p53 is inherently labile, similar to its ...
Reshma eVijayakumaran +6 more
doaj +4 more sources
Targeting oncogenic mutant p53 for cancer therapy [PDF]
Frontiers in Oncology, 2015 Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional p53 ...
Tomoo eIwakuma, Alejandro eParrales
doaj +3 more sources
Targeting the mutant p53 secretome [PDF]
Journal of Clinical Investigation, 2021 While p53 is the most highly mutated and perhaps best studied tumor suppressor protein related to cancer, it remains refractory to targeted therapeutic strategies. In this issue of the JCI, Tan and colleagues investigated the mechanistic basis of the mutant p53 secretome in preclinical models of lung adenocarcinoma.
Kartik Sehgal, David A. Barbie
openaire +2 more sources
A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis [PDF]
Cell Discovery, 2016 AbstractTumor suppressor p53 is the most frequently mutated gene in human tumors. Many tumor-associated mutant p53 (mutp53) proteins gain new tumor-promoting activities, including increased proliferation, metastasis and chemoresistance of tumor cells, which are defined as gain-of-functions (GOFs).
Yue, Xuetian +6 more
openaire +2 more sources
Allele-Specific p53 Mutant Reactivation [PDF]
Cancer Cell, 2012 Rescuing the function of mutant p53 protein is an attractive cancer therapeutic strategy. Using the National Cancer Institute's anticancer drug screen data, we identified two compounds from the thiosemicarbazone family that manifest increased growth inhibitory activity in mutant p53 cells, particularly for the p53(R175) mutant.
Yu, Xin +3 more
openaire +2 more sources
Pharmacological targeting of mutant p53 [PDF]
Translational Cancer Research, 2016 TP53 is the most commonly mutated gene in cancer, with over half of all human cancers harboring a mutation in the gene. The p53 protein is a transcription factor that functions as a tumor suppressor, and a subset of its numerous roles include the arrest of proliferation, promotion of DNA repair, and induction of apoptosis in cells with severe DNA ...
Samuel, Kogan, Darren, Carpizo
openaire +2 more sources
p53’s Extended Reach: The Mutant p53 Secretome [PDF]
Biomolecules, 2020 p53 suppresses tumorigenesis by activating a plethora of effector pathways. While most of these operate primarily inside of cells to limit proliferation and survival of incipient cancer cells, many extend to the extracellular space. In particular, p53 controls expression and secretion of numerous extracellular factors that are either soluble or ...
Evangelos Pavlakis, Thorsten Stiewe
openaire +3 more sources
Mutant p53 succumbs to starvation [PDF]
Cell Cycle, 2013 While the wild type form of p53 possesses strong tumor-suppressive activities, the p53 proteins that are commonly mutated in cancer often endow more malignant properties to the cancers they inhabit. There are several lines of evidence supporting such oncogenic gain of function of mutant p53.
Moon, Sung-Hwan, Prives, Carol L.
openaire +3 more sources
Identification of Small Molecules that Modulate Mutant p53 Condensation
iScience, 2020 Summary: Structural mutants of p53 induce global p53 protein destabilization and misfolding, followed by p53 protein aggregation. First evidence indicates that p53 can be part of protein condensates and that p53 aggregation potentially transitions ...
Clara Lemos +21 more
doaj +1 more source
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Journal of Hematology & Oncology, 2021 TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties.
Jiahao Hu +9 more
doaj +1 more source